Aldeyra Therapeutics

Historical price data

Aldeyra Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapies for immune-mediated diseases through its proprietary Reactive Aldehyde Species (RASP) modulator platform. Its lead asset, reproxalap, is under regulatory review for dry eye disease following a Complete Response Letter, while its pipeline includes ADX-2191 for rare retinal diseases and an oral systemic candidate, ADX-629. The company's strategy hinges on validating its RASP platform through regulatory approval in ophthalmology, then expanding into broader systemic inflammatory and metabolic disorders with significant unmet need.

Reactive Aldehyde Species (RASP) Modulator Platform: A first-in-class approach using small molecules to bind and degrade pathogenic reactive aldehydes that drive inflammation, aiming to downregulate entire pro-inflammatory systems rather than inhibit single protein targets.

In dry eye, reproxalap's primary differentiation is rapid onset of action versus slower, established branded therapies. For its rare retinal programs, ADX-2191's competition is the unsafe standard of care (compounded drugs) or an absence of any therapy, giving it a unique positioning. At the platform level, Aldeyra appears to have a first-mover advantage in targeting RASP.